PDCD1 and non-small cell lung carcinoma: In conclusion, our results suggest high levels of circulating CD4+CD25+CD45RA-FoxP3+ T cells (effector Treg cells) one week after immunotherapy predict a favorable response in NSCLC patients who were treated with either pembrolizumab or nivolumab anti-PD-1 immunotherapy.